Protalix BioTherapeutics (PLX) Interest Expenses (2011 - 2025)
Protalix BioTherapeutics (PLX) posted quarterly Interest Expenses of -$1.3 million for Q4 2025, down 361.84% year-over-year from $511000.0 in Q4 2024, and down 392.78% quarter-over-quarter from $457000.0 in Q3 2025.
Protalix BioTherapeutics (PLX) Interest Expenses (2011 - 2025) Analysis & Trends
Protalix BioTherapeutics' Interest Expenses history runs 15 years deep, the most recent figure standing at -$1.3 million for Q4 2025.
- In Q4 2025, Interest Expenses fell 361.84% year-over-year to -$1.3 million; the TTM figure through Mar 2026 stood at -$881000.0 (down 167.3% YoY), while the FY2025 annual figure was $50.4 million, down 0.59% from the prior year.
- Interest Expenses for Q4 2025 stood at -$1.3 million, down from $457000.0 in the prior quarter.
- The five-year high for Interest Expenses was $2.4 million in Q3 2021, with the low at -$1.3 million in Q4 2025.
- The 5-year median for Interest Expenses is $631000.0 (2022), against an average of $783055.6.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses soared 51200.0% in 2024, then plunged 361.84% in 2025.
- Protalix BioTherapeutics' Interest Expenses stood at $908000.0 in 2021, then fell by 29.63% to $639000.0 in 2022, then slumped by 100.16% to -$1000.0 in 2023, then jumped by 51200.0% to $511000.0 in 2024, then slumped by 361.84% to -$1.3 million in 2025.
- Business Quant data shows PLX's Interest Expenses at -$1.3 million in Q4 2025, $457000.0 in Q3 2025, and $6000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.34 Mn |
| Dec 31, 2025 | -1.34 Mn |
| Sep 30, 2025 | 457,000.00 |
| Sep 30, 2025 | 457,000.00 |
| Mar 31, 2025 | 6,000.00 |
| Mar 31, 2025 | 6,000.00 |
| Dec 31, 2024 | 511,000.00 |
| Dec 31, 2024 | 511,000.00 |
| Sep 30, 2024 | 413,000.00 |
| Sep 30, 2024 | 413,000.00 |
| Jun 30, 2024 | 379,000.00 |
| Jun 30, 2024 | 379,000.00 |
| Mar 31, 2024 | 766,000.00 |
| Mar 31, 2024 | 766,000.00 |
| Dec 31, 2023 | -1,000.00 |
| Dec 31, 2023 | -1,000.00 |
| Sep 30, 2023 | 460,000.00 |
| Sep 30, 2023 | 460,000.00 |
| Jun 30, 2023 | 1.31 Mn |
| Jun 30, 2023 | 1.31 Mn |